ABCELLERA BIOLOGICS
AbCellera focuses on therapeutic antibodies, screening, choosing, and analyzing millions of naturally produced antibodies to be used as next-generation drug candidates. It specializes in the fields of biotechnology, medicine, and therapeutics.
ABCELLERA BIOLOGICS
Industry:
Biotechnology Medical Therapeutics
Founded:
2012-01-01
Status:
Active
Contact:
(604) 559-9005
Total Funding:
371.22 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Nginx Amazon IPv6 Google Apps For Business Microsoft Azure DNS
Similar Organizations
Rakuten Medical
Rakuten Medical is a Bio-technology Company.
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2021-09-13 | Tetragenetics | Tetragenetics acquired by AbCellera Biologics | N/A |
| 2020-11-18 | Trianni | Trianni acquired by AbCellera Biologics | 90 M USD |
| 2020-08-20 | Dualogics - OrthoMab | Dualogics - OrthoMab acquired by AbCellera Biologics | N/A |
| 2018-08-01 | Lineage Biosciences | Lineage Biosciences acquired by AbCellera Biologics | N/A |
Investors List
Eli Lilly
Eli Lilly investment in Series B - AbCellera Biologics
Presight Capital
Presight Capital investment in Series B - AbCellera Biologics
Founders Fund
Founders Fund investment in Series B - AbCellera Biologics
OrbiMed
OrbiMed investment in Series B - AbCellera Biologics
DCVC
DCVC investment in Series B - AbCellera Biologics
Peter Thiel
Peter Thiel investment in Series B - AbCellera Biologics
Viking Global Investors
Viking Global Investors investment in Series B - AbCellera Biologics
University of Minnesota
University of Minnesota investment in Series B - AbCellera Biologics
Government of Canada
Government of Canada investment in Grant - AbCellera Biologics
Founders Fund
Founders Fund investment in Series A - AbCellera Biologics
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2020-09-30 | Invetx | AbCellera Biologics investment in Series A - Invetx | 10.25 M USD |
| 2020-02-24 | Invetx | AbCellera Biologics investment in Series A - Invetx | 15 M USD |
Key Employee Changes
| Date | New article |
|---|---|
| 2021-07-13 | AbCellera Appoints Neil Berkley as Chief Business Officer |
More informations about "AbCellera Biologics"
AbCellera - Wikipedia
AbCellera Biologics Inc. is a Vancouver, British Columbia -based contract research organization (CRO) that is contracted by biotechnology and pharmaceutical companies for antibody …See details»
AbCellera - Crunchbase Company Profile & Funding
AbCellera is an antibody discovery and development company that develops antibody therapeutics to improve patient outcomes.See details»
AbCellera Biologics Inc Company Profile - Overview - GlobalData
AbCellera Biologics Inc (AbCellera) is a biotechnology company that discovers and develops next-generation therapeutic antibodies for cancer, metabolic and endocrine conditions, and …See details»
AbCellera Biologics Inc. (ABCL) - Yahoo Finance
Find the latest AbCellera Biologics Inc. (ABCL) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
AbCellera's Pipeline
We are advancing programs to address unmet medical need in autoimmunity, endocrine and metabolic conditions, and beyond.See details»
Canada and British Columbia invest in AbCellera’s state-of-the-art ...
May 24, 2023 News release AbCellera will strengthen Canada’s ability to develop innovative medicines right here at home May 24, 2023 – Vancouver, British Columbia The Government of …See details»
AbCellera - Wikiwand
AbCellera Biologics Inc. is a Vancouver, British Columbia -based contract research organization (CRO) that is contracted by biotechnology and pharmaceutical companies for antibody …See details»
AbCellera Biologics: Unraveling its Core Product …
Oct 28, 2023 In the intricate tapestry of the biotech sector, AbCellera Biologics emerges as a standout, merging the power of AI with the complexities of antibody discovery. This entity is driven by the ...See details»
AbCellera: Just Another Biotech Stock - Seeking Alpha
Jul 23, 2025 Company Overview AbCellera Biologics Inc. is a technology-enabled healthcare company that is focused on the development of antibody-based drugs. The Company's …See details»
AbCellera Biologics Inc. - Investor Relations
Jul 7, 2025 AbCellera (Nasdaq: ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, …See details»
AbCellera Biologics (ABCL) Advances Proprietary Pipeline with …
2 days ago AbCellera Biologics Inc. (NASDAQ:ABCL) is a biotech company specializing in discovering and developing therapeutic antibodies across various disease areas, including …See details»
AbCellera Biologics (ABCL) Stock Analysis Report - Benzinga
3 days ago Get the latest AbCellera Biologics (ABCL) stock analysis report: in-depth insights, analyst ratings, financials, and historical performance. Updated August 2025 for smarter …See details»
AbCellera's News & Events
Stay up to date with AbCellera's latest news & events posts.See details»
AbCellera's Platforms
AbCellera's platform integrates biology, computation, and engineering to create innovative antibody-based medicines from target discovery to clinical development.See details»
AbCellera Reports Q2 2025 Business Results & First Participants …
Aug 7, 2025 VANCOUVER, British Columbia, August 07, 2025--AbCellera Reports Q2 2025 Business Results & Initiation of a Phase 1 Clinical Trial of ABCL635 for Vasomotor SymptomsSee details»
AbCellera's Publications
Explore AbCellera's scientific publications and presentations on antibody drug development and innovative technologies.See details»
AbCellera Biologics Inc. - AbCellera Continues Expansion and ...
Jun 22, 2021 In parallel with the construction of the new facility, AbCellera is also building up an internal Chemistry Manufacturing and Controls (CMC) development organization – the team of …See details»
Industry Analysts Just Made A Huge Upgrade To Their AbCellera …
Aug 12, 2025 Following the upgrade, the current consensus from AbCellera Biologics' nine analysts is for revenues of US$34m in 2025 which - if met - would reflect a reasonable 3.0% …See details»
AbCellera Biologics Inc (ABCL) Q2 2025 Earnings Call Highlights ...
Aug 8, 2025 AbCellera Biologics Inc (ABCL) reports significant revenue growth and advances in clinical trials, despite ongoing net losses.See details»
About AbCellera
We are an early-stage biotech creating medicines that improve people’s lives by addressing conditions with high unmet medical need.See details»